Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Preferred Dividend Payments (2016 - 2025)

Guided Therapeutics' Preferred Dividend Payments history spans 13 years, with the latest figure at $43000.0 for Q3 2025.

  • For Q3 2025, Preferred Dividend Payments rose 13.16% year-over-year to $43000.0; the TTM value through Sep 2025 reached $172000.0, down 1.71%, while the annual FY2024 figure was $174000.0, 1.75% up from the prior year.
  • Preferred Dividend Payments for Q3 2025 was $43000.0 at Guided Therapeutics, down from $45000.0 in the prior quarter.
  • Across five years, Preferred Dividend Payments topped out at $548000.0 in Q1 2022 and bottomed at -$55000.0 in Q1 2021.
  • The 5-year median for Preferred Dividend Payments is $48000.0 (2022), against an average of $91141.8.
  • The largest annual shift saw Preferred Dividend Payments plummeted 558.33% in 2021 before it soared 1096.36% in 2022.
  • A 5-year view of Preferred Dividend Payments shows it stood at $346694.0 in 2021, then tumbled by 85.58% to $50000.0 in 2022, then decreased by 2.0% to $49000.0 in 2023, then decreased by 2.04% to $48000.0 in 2024, then dropped by 10.42% to $43000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Preferred Dividend Payments are $43000.0 (Q3 2025), $45000.0 (Q2 2025), and $36000.0 (Q1 2025).